Home > Result Summaries: Compounds > naratriptan > Result Summary for S2W40024

Result Summary for S2W40024

Result Summary

Protocol ID:	S2W40024
Clinical Study ID:	S2W40024
Official Title:	A Randomised, Double-Blind, Placebo-Controlled, Parallel Group Evaluation of Oral Naratriptan 1mg TwiceDaily as Prophylactic Treatment for Menstrually-Associated Migraine.
Phase:	Phase 4
Study Indications or Diseases:	Migraine Disorders
Generic Name:	naratriptan
Trade/Product Name:	amerge;naramig
Approved Drug Label:	http://www.gsk.com/products.html
Results Summary:	Click here to download result summary.
Citations:	Savani N, Loftus J, Mansbach H, Scott A. A randomized, double-blind, placebo-controlled, parallel group evaluation of oral naratriptan 1mg twice daily as prophylactic treatment for menstrually-associated migraine. Poster Presentation at the 6th European Headache Congress, Istanbul, Turkey. June 17, 2002 - June 22, 2002. Mannix LK et al. Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies. Headache 2007;47:1037-1049. Abstract: Patient satisfaction with oral naratriptan for intermittent prophylaxis of menstrually associated migraine: results from a double-blind, placebo-controlled, parallel group study. Kwong, J. W., Putnam, G. D., Loftus, J. V., Ames, M. H., and Shackelford, S. R. 45th Annual Scientific Meeting of the American Headache Society (AHS) 6/19/2003 Chicago, IL, USA Abstract: Patient satisfaction with oral naratriptan for intermittent prophylaxis of menstrually associated migraine (mam): results from a double-blind, placebo-controlled, parallel group study. Savani, N. , Kwong, W. J., Putnam, D. G., Ames, M. H. , Loftus, J. V., and Shackelford, S. R. 7th Congress of the European Federation of Neurological Societies (EFNS) 8/30/2003 Helsinki, Finland